The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.

Heart rate variability biofeedback (HRVB) can reduce negative affect, craving, and substance use among individuals in early recovery from substance use disorder (SUD).

A mother’s death during or after pregnancy increases the risk for the infant’s death or hospitalization, according to a study.

Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.

A higher proportion of adolescents who tested positive for COVID-19 reported ongoing symptoms compared with those who tested negative or never tested.

Patients with various combinations of CKM comorbidities who receive GLP-1RAs have decreased risk for HF hospitalization and CV death.

Early natural menopause and surgical menopause are linked to women's employment trajectories, according to a study published online.

Topline data were announced from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes.

Long COVID remains globally prevalent following COVID-19 infection, with a significant burden of symptoms lasting 1 to 2 years postinfection.

There is decreased risk for hospitalization in patients with heart failure who receive a high-dose inactivated influenza vaccine.

The U.S. Food and Drug Administration (FDA) has approved Lasix ONYU (furosemide injection), a new drug-device combination developed by SQ Innovation, Inc., for treating edema caused by chronic heart ...

A novel color perimeter may serve as a potential tool to detect subtle visual changes dueto glucose dysfunction in preclinical diabetes.